A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-4416PMID 17440059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2007

  2007cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Targeting Tyrosine Kinases in Cancer: The Second Wave

  2006cited by this paper
• A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

  2005cited by this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005influential reference
• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  2005cited by this paper
• The Sema domain of Met is necessary for receptor dimerization and activation.

  2004cited by this paper
• The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.

  2004cited by this paper
• A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

  2003cited by this paper
• Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways

  2003cited by this paper
• c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

  2003influential reference
• A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

  2003cited by this paper
• Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.

  2003cited by this paper
• Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

  2002cited by this paper
• A role for common fragile site induction in amplification of human oncogenes.

  2002cited by this paper
• Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region.

  2001cited by this paper
• Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.

  1997cited by this paper
• Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.

  1996cited by this paper
• Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity.

  1994cited by this paper
• Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.

  1990cited by this paper

• Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance

  2025cites this paper
• Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds

  2025cites this paper
• The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

  2024cites this paper
• Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma

  2024cites this paper
• Deficiency of germinal center kinase TRAF2 and NCK-interacting kinase (TNIK) in B cells does not affect atherosclerosis

  2023cites this paper
• OTT_A_317122 4791..4804

  2021cites this paper
• A c-Met Inhibitor Suppresses Osteosarcoma Progression via the ERK1/2 Pathway in Human Osteosarcoma Cells

  2021cites this paper
• Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Mechanisms of Peritoneal Metastasis Formation

  2020cites this paper
• Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells

  2019cites this paper
• A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway

  2019cites this paper
• MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

  2019cites this paper
• 12-25-2018 Targeted Therapies for Advanced Non-Small Cell Lung Cancer

  2019cites this paper
• Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization

  2019influential citation
• Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects

  2018cites this paper
• Citrus reticulata peel oil inhibits non-small cell lung cancer cell proliferation in culture and implanted in nude mice.

  2018cites this paper
• Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway.

  2018cites this paper
• Targeted therapies for advanced non-small cell lung cancer

  2018cites this paper
• Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism

  2017cites this paper
• Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression

  2017cites this paper
• Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome

  2017cites this paper
• Semaphorin 4C Plexin-B2 signaling in peripheral sensory neurons is pronociceptive in a model of inflammatory pain

  2017cites this paper
• Modulation of Bax and mTOR for Cancer Therapeutics.

  2017cites this paper
• MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer

  2017cites this paper
• PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma.

  2017cites this paper
• Madecassoside ameliorates bleomycin‐induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR‐γ in colon

  2016influential citation
• Targeting c‐MET by LY2801653 for treatment of cholangiocarcinoma

  2016cites this paper
• c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo.

  2016cites this paper
• Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance

  2016cites this paper
• Preclinical evaluation of Meriva (a formulation of curcumin) as a putative agent for chemoprevention of lung cancer

  2016cites this paper
• cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer

  2016cites this paper
• Targeted therapy in esophageal cancer

  2016cites this paper
• Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide

  2015cites this paper
• Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis

  2015cites this paper
• Molecular Mechanism of Peritoneal Metastases

  2015cites this paper
• TGF-β Negatively Regulates CXCL1 Chemokine Expression in Mammary Fibroblasts through Enhancement of Smad2/3 and Suppression of HGF/c-Met Signaling Mechanisms

  2015cites this paper
• Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.

  2015cites this paper
• Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

  2015cites this paper
• Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

  2015cites this paper
• Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer

  2015cites this paper
• Small-Molecule Inhibitor of c-Met , PF-2341066 , Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis 1

  2014cites this paper
• Cell Lines Expressing Recombinant Transmembrane Domain–Activated Receptor Kinases as Tools for Drug Discovery

  2014cites this paper
• Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

  2014cites this paper
• Targeting the MeT receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

  2014cites this paper
• Targeting the MeT receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

  2014cites this paper
• Targeting the MeT receptor tyrosine kinase in non-small cell lung cancer : emerging role of tivantinib eberechi

  2014cites this paper
• Targeting c-Met in melanoma

  2014cites this paper
• Small Molecule Bax Agonists for Cancer Therapy

  2014cites this paper
• Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches

  2014cites this paper
• Dynamics of tissue morphogenesis

  2014cites this paper
• Para- and Autocrine Mediators in the Glioma Microenvironment

  2014cites this paper
• ROLE OF CXCL1 SIGNALING IN STROMA: EPITHELIUM INTERACTIONS DURING BREAST CANCER PROGRESSION

  2014cites this paper
• Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

  2014cites this paper
• Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.

  2014cites this paper
• HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and Therapeutics

  2013influential citation
• Angiogenesis and Vascularisation

  2013cites this paper
• The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

  2013cites this paper
• Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.

  2013cites this paper
• Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma

  2013cites this paper
• Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells

  2013cites this paper
• Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.

  2013cites this paper
• Angiogenic Signaling and Structural Abnormalities in Tumors

  2013cites this paper
• Targeting the Met pathway in lung cancer

  2012cites this paper
• Novel treatment avenues for peripheral T-cell lymphomas

  2012influential citation
• MET inhibitors in combination with other therapies in non-small cell lung cancer.

  2012cites this paper
• MET expression in melanoma correlates with a lymphangiogenic phenotype.

  2012cites this paper
• The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer

  2012cites this paper
• Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells.

  2012cites this paper
• Targeting MET in cancer: rationale and progress

  2012cites this paper
• MET targeted therapy for lung cancer: clinical development and future directions.

  2012cites this paper
• Structure-based anti-cancer drug development by targeting Bcl-XL

  2012cites this paper
• Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

  2011cites this paper
• Altered Signal Transduction Pathways in Melanoma

  2011cites this paper
• Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

  2011cites this paper
• Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function*

  2011cites this paper
• DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma

  2011cites this paper
• MicroRNAs in development and disease.

  2011cites this paper
• Novel strategies for the treatment of small-cell lung carcinoma

  2011cites this paper
• Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa.

  2011cites this paper
• Intro The lignan plastic inhibi

  2010cites this paper
• Autophagy Induction with RAD001 Enhances Chemosensitivity and Radiosensitivity through Met Inhibition in Papillary Thyroid Cancer

  2010cites this paper
• In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor.

  2010cites this paper
• MET molecular mechanisms and therapies in lung cancer

  2010cites this paper
• Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling

  2010cites this paper
• Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action

  2010cites this paper
• Cancer esearch apeutics , Targets , and Chemical Biology T and KRAS Gene Amplification Mediates Acquired R istance to MET Tyrosine Kinase Inhibitors

  2010cites this paper
• Adipose Stroma Induces Branching Morphogenesis of Engineered Epithelial Tubules

  2010cites this paper
• Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.

  2010cites this paper
• Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma.

  2010cites this paper
• MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.

  2010cites this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

  2010cites this paper
• Cycle , Cell Death , and Senescence ophagy Induction with RAD 001 Enhances mosensitivity and Radiosensitivity through R Inhibition in Papillary Thyroid Cancer

  2010cites this paper
• The Ron receptor tyrosine kinase in prostate cancer.

  2010cites this paper
• C-MET as a new therapeutic target for the development of novel anticancer drugs

  2010cites this paper
• A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

  2010influential citation
• HGF/c-MET Signaling in Advanced Cancers

  2010cites this paper
• Quantitative Proteomics Discloses MET Expression in Mitochondria as a Direct Target of MET Kinase Inhibitor in Cancer Cells*

  2010cites this paper
• Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.

  2010cites this paper
• Preferential binding of anti-cancer drug adriamycin to the Sp1 binding site in c-met promoter region: A spectroscopic and molecular modeling study

  2009cites this paper
• MET receptor tyrosine kinase.

  2009cites this paper